Dermatology Times, May 2020 (Vol. 41, No. 5)

IL-23 antagonist demonstrates favorable long-term safety

May 06, 2020

The interleukin-23 antagonist guselkumab demonstrated greater efficacy compared with adalimumab and secukinumab at week 48 in controlled clinical trials investigating treatment of moderate-to-severe plaque psoriasis.

The future of actinic keratosis treatment

May 04, 2020

It is estimated that 0.025% to 16% of all actinic keratosis (AK) lesions may progress into invasive SCC per year, and there is still no marker to predict which lesions will progress, according to a recent paper that outlined diagnostic challenges as well as current and pipeline treatment approaches.

Molecular study highlights drug differences in atopic dermatitis

April 20, 2020

A recent meta-analysis confirms cyclosporine as the most effective atopic dermatitis (AD) treatment at the molecular level, although dupilumab achieves broad cutaneous changes beyond those expected with specific Th2 inhibition.

Combining psoriasis topicals yields unpredictable results

March 24, 2020

Dermatologists often combine multiple topical agents on their own, and have been doing so for many years. However, extemporaneous compounding of psoriasis topical agents may not necessarily yield what dermatologists anticipate.

Investigational cream may be effective to deliver tranexamic acid

January 29, 2020

Melasma responds well to oral and locally injected tranexamic acid treatments, but clinical results from topical tranexamic acid administration have been disappointing, researchers report. They examined efficacy of a co-enhancer as a method to deliver the treatment.

Skin microbiome as clinical biomarker for atopic dermatitis

January 21, 2020

With advancements in deep next-generation sequencing (NGS) and bioinformatics analysis, the authors of a recent study suggest the skin microbiome may hold promise as a clinical biomarker in atopic dermatitis (AD) management.